Hettasch J M, Bandarenko N, Burchette J L, Lai T S, Marks J R, Haroon Z A, Peters K, Dewhirst M W, Iglehart J D, Greenberg C S
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
Lab Invest. 1996 Nov;75(5):637-45.
Tissue transglutaminase (tTG) is postulated to play a role in apoptosis, cell adhesion, metastasis, and extracellular matrix (ECM) assembly. In this study, the distribution and expression of tissue transglutaminase was investigated in normal human mammary tissue and in intraductal and invasive human breast cancer by immunohistochemistry and in situ hybridization. Frozen and formalin-fixed paraffin-embedded sections of normal, intraductal, and invasive human breast carcinoma were examined with an avidin-biotin complex immunoperoxidase method for tTG antigen and by in situ hybridization to determine the cell types expressing tTG mRNA. The expression of tTG in normal and malignant mammary epithelium in culture was evaluated by quantitative immunoblot analysis. Low-level expression of tTG was found in normal tissues with the antigen located in the ECM surrounding the ducts and in the endothelium. In intraductal cancer, there was a marked increased expression of the tTG antigen, and the increased staining was found in the ECM and was also localized in a distinct pattern at the boundary between the in situ tumor cells and the normal tissue. Further immunohistochemical analysis revealed that the cells in this boundary also stained for the endothelial cell markers CD31, CD34, and von Willebrand factor. In invasive tumors, the tTG antigen was no longer localized to the normal tissue/tumor boundary but dispersed around the tumor cells. In situ hybridization studies revealed three distinct compartments of tTG synthesis: (a) tumor cells, (b) endothelial cells, and (c) stromal cells. In addition, normal and malignant epithelial cells in culture expressed variable amounts of tTG, and the expression of tTG in these epithelial cells was at least 17-fold less than endothelial cells. The up-regulation of tTG in intraductal and invasive human breast cancer and its localization to the ECM and neovasculature suggest that tTG may regulate tumor growth and metastasis.
组织转谷氨酰胺酶(tTG)被认为在细胞凋亡、细胞黏附、转移以及细胞外基质(ECM)组装中发挥作用。在本研究中,通过免疫组织化学和原位杂交技术,对正常人类乳腺组织、导管内癌和浸润性人类乳腺癌中组织转谷氨酰胺酶的分布和表达进行了研究。采用抗生物素蛋白-生物素复合物免疫过氧化物酶法检测正常、导管内和浸润性人类乳腺癌的冰冻切片及福尔马林固定石蜡包埋切片中的tTG抗原,并通过原位杂交确定表达tTG mRNA的细胞类型。通过定量免疫印迹分析评估培养的正常和恶性乳腺上皮细胞中tTG的表达。在正常组织中发现tTG低水平表达,抗原位于导管周围的ECM和内皮细胞中。在导管内癌中,tTG抗原表达明显增加,增加的染色见于ECM,并且也以独特的模式定位于原位肿瘤细胞与正常组织之间的边界。进一步的免疫组织化学分析显示,该边界处的细胞也表达内皮细胞标志物CD31、CD34和血管性血友病因子。在浸润性肿瘤中,tTG抗原不再定位于正常组织/肿瘤边界,而是分散在肿瘤细胞周围。原位杂交研究揭示了tTG合成的三个不同区域:(a)肿瘤细胞,(b)内皮细胞,和(c)基质细胞。此外,培养的正常和恶性上皮细胞表达不同量的tTG,这些上皮细胞中tTG的表达比内皮细胞至少低17倍。导管内和浸润性人类乳腺癌中tTG的上调及其在ECM和新生血管中的定位表明,tTG可能调节肿瘤生长和转移。